Condition
    Moderate Evidence
    Effectiveness 1/5

    Omega-3 Fatty Acids for Ischemic Stroke

    Despite strong observational signals, omega-3 has not prevented stroke in adequately powered trials.

    Overview

    Despite strong observational signals, omega-3 has not prevented stroke in adequately powered trials.

    Verdict

    Not supported

    Large randomised prevention trials found no reduction in stroke, and high doses raise atrial fibrillation risk.

    How It Works

    EPA and DHA lower triglycerides, reduce platelet aggregation and have modest anti-inflammatory effects, which generated the hypothesis that they would reduce atherothrombotic events including stroke. The failure of that hypothesis in trials illustrates the gap between plausible mechanism and clinical outcome.

    Dosing & Protocol

    Typical dose

    Recommended dose
    No stroke-prevention dose is supported; 1 g daily is reasonable only where indicated for other reasons
    Expected timeframe
    No stroke benefit demonstrated at any duration studied

    Protocol

    form
    Not applicable
    duration
    Not applicable
    co factor
    The verdict is no: large randomised trials and meta-analyses, including VITAL and ASCEND, tested 840-1000 mg/day combined EPA+DHA and found no reduction in stroke incidence or recurrence. Antiplatelet or anticoagulant therapy, blood-pressure control, statins, atrial fibrillation management and smoking cessation are the interventions that prevent stroke.
    titration
    Not applicable
    starting dose
    Not indicated for stroke prevention

    Evidence

    What the studies say

    The VITAL trial randomised over 25,000 adults to 840 mg daily of omega-3 and found no reduction in stroke or in the composite cardiovascular endpoint. ASCEND, in 15,480 people with diabetes, similarly found no vascular benefit. REDUCE-IT, using 4 g of icosapent ethyl in high-risk patients with elevated triglycerides, did show a reduction in the composite endpoint including stroke, but the mineral oil comparator has been widely criticised and the result has not been replicated. Meta-analyses of stroke specifically show no significant reduction. Two safety findings matter: higher doses were associated with increased atrial fibrillation incidence across several trials, and atrial fibrillation is itself a major cause of cardioembolic stroke. Antiplatelet therapy, statins and blood pressure control remain the interventions with proven secondary prevention benefit.

    No studies are yet linked to both Omega-3 Fatty Acids and Ischemic Stroke.

    Safety

    Caveats

    Doses of 4 g daily increased atrial fibrillation incidence in randomised trials. Bleeding risk rises with antiplatelet or anticoagulant therapy, which most stroke patients take.

    Less likely to help if

    Anyone taking omega-3 specifically to prevent stroke — the trial evidence does not support this use.

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.